title: Refractory plasmablastic lymphoma-a review of treatment options beyond standard therapy.
abstract: Plasmablastic lymphoma (PBL) is a rare distinct subtype of aggressive diffuse large B-cell lymphoma and a notoriously hard to treat entity with a dismal prognosis in both HIV-negative and HIV-positive patients. Clinicians often face the question of second or third line treatment. As the treatment options with novel agents in lymphomas are rapidly evolving, more and more options beyond standard chemotherapy are available. In connection with a review of treatment options with novel lymphoma agents, we present a case report of a patient with a complete remission after the administration of brentuximab vedotin and lenalidomide.
authors.affiliation: Hematology and Medical Oncology Clinic, Nuremberg General Hospital, Paracelsus Medical University, Prof.-Ernst-Nathan-Str. 1, D-90419, Nuremberg, Germany. dominik.pretscher@klinikum-nuernberg.de.
authors.forename: Dominik
authors.initials: D
authors.lastname: Pretscher
authors.affiliation: Hematology and Medical Oncology Clinic, Nuremberg General Hospital, Paracelsus Medical University, Prof.-Ernst-Nathan-Str. 1, D-90419, Nuremberg, Germany.
authors.forename: Alexander
authors.initials: A
authors.lastname: Kalisch
authors.affiliation: Hematology and Medical Oncology Clinic, Nuremberg General Hospital, Paracelsus Medical University, Prof.-Ernst-Nathan-Str. 1, D-90419, Nuremberg, Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Wilhelm
authors.affiliation: Hematology and Medical Oncology Clinic, Nuremberg General Hospital, Paracelsus Medical University, Prof.-Ernst-Nathan-Str. 1, D-90419, Nuremberg, Germany.
authors.forename: Josef
authors.initials: J
authors.lastname: Birkmann
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000079963:Brentuximab Vedotin; D019008:Drug Resistance, Neoplasm; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage; D000077269:Lenalidomide; D008297:Male; D000069293:Plasmablastic Lymphoma / Q000175:diagnosis* / Q000188:drug therapy*; D011379:Prognosis; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D016896:Treatment Outcome
chemical_list: D018796:Immunoconjugates; D013792:Thalidomide; D000079963:Brentuximab Vedotin; D000077269:Lenalidomide
keywords: Brentuximab; Lenalidomide; Plasmablastic lymphoma; Refractory; Review